CD4 and neoplasm: Transfer of AMHR2-CD-specific CD4+ T cells purified from 4-week primed splenocytes resulted in significant inhibition of ID8 tumor growth compared to transfer of purified OVA-specific CD4+ T cells (P < 0.0004, Figure 6(d)) whereas transfer of AMHR2-CD-primed B220+ B cells purified from 4-week primed splenocytes did not significantly inhibit ID8 tumor growth compared to transfer of OVA-primed B220+ B cells (P = 0.07, Figure 6(d)).